@Alacris Theranostics GmbH – Innovation leader in precision oncology!
“We want every cancer patient to have a bright future”
🔬 Join the Forefront of Cancer Molecular Diagnostics
Our mission is to empower every cancer patient with the benefits of precision medicine. With a passionate team translating research into patient-centered diagnostic solutions, we offer best-in-class accredited Dx services that combine state-of-the-art Next Generation Sequencing (NGS) with our proprietary bioinformatics pipeline.
🧬 Unleash the Power of Comprehensive Tumor Profiling
Experience a unique personalized Dx with our flagship solution, the Alacris-CMTA-TM (Comprehensive Molecular Tumor Analysis). By seamlessly integrating genomics and bulk transcriptomics, our ISO 15189 accredited CMTA Dx test provides unparalleled insights into somatic alterations and the tumor microenvironment. Unlocking potential drug targets, the CMTA actionable report empowers the oncologist to offer the best possible care, ultimately leading to improved outcomes.
🧬 Experience Our Outstanding NGS Services
We harness the remarkable power of DNBSEQ-TM technology, developed by MGI, to provide NGS services of the highest quality. We operate medium (G400) to ultra-high throughput (T7) sequencers to accommodate a wide range of applications: whole genome / exome / RNA sequencing (WGS, WES, RNA-seq) and more. Trusted by clinical laboratories, academic institutions, and pharma alike, we also proudly serve the MMHP Million Microbiome Human Project.
🌍 Shaping the Future of Precision Medicine
Discover ModCell-TM, our award-winning proprietary in silico mechanistic modeling technology that enables the simulation of patient-specific drug responses. Setting new benchmarks in pre-clinical cancer research, ModCell-TM paves the way for transformative advances in precision oncology.
🔗 To learn more about us, visit www.alacris-theranostics.com and join us in our journey to precision medicine excellence
